<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634231</url>
  </required_header>
  <id_info>
    <org_study_id>07-098</org_study_id>
    <nct_id>NCT00634231</nct_id>
    <nct_alias>NCT00729105</nct_alias>
  </id_info>
  <brief_title>A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors</brief_title>
  <official_title>A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candel Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Candel Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the administration of AdV-tk followed by valacyclovir in children&#xD;
      with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma&#xD;
      (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary&#xD;
      objective is to determine if this approach is safe and can be effectively delivered without&#xD;
      disturbing standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Open label, Phase I, dose escalation study. Patients will receive an injection of&#xD;
      AdV-tk into the tumor or tumor bed during the surgical procedure followed by 14 days of&#xD;
      anti-herpetic prodrug, valacyclovir, starting 1-3 days after vector injection. Standard&#xD;
      radiotherapy will begin 3-7 days after AdV-tK injection. Standard chemotherapy may begin&#xD;
      after completion of valacyclovir at the discretion of the treating physician and family. Two&#xD;
      dose levels of AdV-tk will be evaluated with a fixed dose of valacyclovir.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based on standard laboratory and clinical adverse event monitoring</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic function</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Malignant Glioma</condition>
  <condition>Recurrent Ependymoma</condition>
  <arm_group>
    <arm_group_label>AdV-tk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdV-tk + valacyclovir in combination with standard of care radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdV-tk</intervention_name>
    <arm_group_label>AdV-tk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <arm_group_label>AdV-tk</arm_group_label>
    <other_name>Prodrug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>AdV-tk</arm_group_label>
    <other_name>Radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 3 years of age or older&#xD;
&#xD;
          -  Patients must be planning to undergo standard of care treatment with surgery and&#xD;
             radiation therapy.&#xD;
&#xD;
          -  Patients must have malignant glioma or recurrent ependymoma&#xD;
&#xD;
          -  Tumor must be accessible for injection and must not be located in the brainstem or&#xD;
             deep midbrain&#xD;
&#xD;
          -  Performance Score: Karnofsky ≥60% if &gt;10y/o, Lansky ≥60 if ≤10y/o&#xD;
&#xD;
          -  Bone Marrow Function: Patients must have adequate bone marrow function defined as a&#xD;
             peripheral absolute neutrophil count ≥ 1000/µl, platelet count ≥ 100,000/µl&#xD;
             (transfusion independent) and hemoglobin ≥ 8.0 gm/dL&#xD;
&#xD;
          -  Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of&#xD;
             institutional normal for age and/or GFR ≥ 70 mL/min/1.73 m2.&#xD;
&#xD;
          -  Hepatic Function: Bilirubin ≤ 1.5 times institutional normal; SGPT (ALT) &lt; 3 times&#xD;
             institutional normal&#xD;
&#xD;
          -  Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior&#xD;
             to enrollment and clinically significant abnormalities corrected prior to&#xD;
             surgery/AdV-tk injection&#xD;
&#xD;
          -  Patients with seizure disorder may be enrolled if well controlled&#xD;
&#xD;
          -  Signed informed consent according to institutional guidelines must be obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection&#xD;
             but not to exclude patients with a distant history of resolved hepatitis A infection&#xD;
&#xD;
          -  Patients on immunosuppressive drugs (with exception of corticosteroid)&#xD;
&#xD;
          -  Known history of HIV or underlying immunodeficiency&#xD;
&#xD;
          -  Patients with acute infections (viral, bacterial or fungal infections requiring&#xD;
             therapy)&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Female patients of childbearing age must have&#xD;
             negative serum or urine pregnancy test within 1 week of beginning therapy&#xD;
&#xD;
          -  Other serious co-morbid illness or compromised organ function&#xD;
&#xD;
          -  No other investigational anti-tumor agents within 30 days prior to study entry or&#xD;
             during active participation in the study (defined as from study entry until tumor&#xD;
             progression)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, Polanco MLS, Guzik BW, Aguilar-Cordova E, Diaz-Montero CM, DiPatri AJ, Tomita T, Lulla R, Greenspan L, Aguilar LK, Goldman S. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019 Mar 18;21(4):537-546. doi: 10.1093/neuonc/noy202.</citation>
    <PMID>30883662</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant glioma</keyword>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>Anaplastic astrocytoma</keyword>
  <keyword>Recurrent ependymoma</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

